Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UBE-Q phase II trial of ubenimex with pembrolizumab + nab-paclitaxel + carboplatin in untreated advanced squamous NSCLC
jRCT2031210707Phase 2Active, not recruiting
- Sponsor
- Nippon Kayaku Co., Ltd.
- Start
- Jan 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ubenimex, pembrolizumab, paclitaxel and carboplatin in Pulmonary squamous cell carcinoma, sponsored by Nippon Kayaku Co., Ltd. Primary endpoint: Response rate by central response evaluation. Started Jan 2023; status: active, not recruiting.
02
Drugs
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on jRCT2031210707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210707.